Reginald L Dean

Summary

Affiliation: Alkermes Inc
Country: USA

Publications

  1. ncbi The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence
    Reginald L Dean
    Department of Life Sciences, Alkermes, Inc, 88 Sidney Street, Cambridge, MA 02139, USA
    Front Biosci 10:643-55. 2005
  2. ncbi Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone
    Reginald L Dean
    Department of Life Sciences and Toxicology, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    Pharmacol Biochem Behav 89:515-22. 2008
  3. ncbi Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats
    Reginald L Dean
    Life Sciences and Toxicology, Alkermes, Inc, Waltham, MA 02451, USA
    Pharmacol Biochem Behav 100:530-7. 2012
  4. ncbi Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats
    Mark S Todtenkopf
    Department of Life Sciences and Toxicology, Alkermes, Inc, USA
    Addict Biol 14:408-18. 2009
  5. ncbi Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    Raymond T Bartus
    Alkermes, Inc, Cambridge, MA, USA
    Neuropsychopharmacology 28:1973-82. 2003
  6. ncbi Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps
    Raymond T Bartus
    Ceregene, Inc, 9381 Judicial Dr, Suite 130, San Diego, CA 92121, USA
    Psychopharmacology (Berl) 202:15-36. 2009
  7. ncbi Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions
    Dwaine F Emerich
    Alkermes, Inc, Cambridge, Massachusetts 02139, USA
    Pharm Res 19:1052-60. 2002

Detail Information

Publications7

  1. ncbi The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence
    Reginald L Dean
    Department of Life Sciences, Alkermes, Inc, 88 Sidney Street, Cambridge, MA 02139, USA
    Front Biosci 10:643-55. 2005
    ..Both naltrexone and the PLG polymer matrix in which it is encapsulated are well tolerated. Clinical trials of Vivitrex are currently ongoing in alcohol dependent patients...
  2. ncbi Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone
    Reginald L Dean
    Department of Life Sciences and Toxicology, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    Pharmacol Biochem Behav 89:515-22. 2008
    ..Thus, opioid receptor blockade with XR-NTX can be overcome in rats with higher doses of opioids without further affecting respiration or locomotor activity...
  3. ncbi Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats
    Reginald L Dean
    Life Sciences and Toxicology, Alkermes, Inc, Waltham, MA 02451, USA
    Pharmacol Biochem Behav 100:530-7. 2012
    ..These data suggest an important role for opioid receptors within the GIT in modulating central reward pathways and may provide new insights into strategies for treating reward disorders, including drug dependency...
  4. ncbi Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats
    Mark S Todtenkopf
    Department of Life Sciences and Toxicology, Alkermes, Inc, USA
    Addict Biol 14:408-18. 2009
    ..In summary, an extended-release formulation of naltrexone results in significant attenuation of psychostimulant-enhanced BSR that is not observed with acute naltrexone...
  5. ncbi Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    Raymond T Bartus
    Alkermes, Inc, Cambridge, MA, USA
    Neuropsychopharmacology 28:1973-82. 2003
    ..Clinical trials of extended release naltrexone for treating alcohol and opiate dependency are currently ongoing...
  6. ncbi Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps
    Raymond T Bartus
    Ceregene, Inc, 9381 Judicial Dr, Suite 130, San Diego, CA 92121, USA
    Psychopharmacology (Berl) 202:15-36. 2009
    ..This effort produced several notable findings that eventually received consensus support, which we have been asked to review...
  7. ncbi Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions
    Dwaine F Emerich
    Alkermes, Inc, Cambridge, Massachusetts 02139, USA
    Pharm Res 19:1052-60. 2002
    ..However, attention must be paid to the placement of the microspheres, for injections around the tumor perimeter may be required for efficacy...